Cogent continues to actively enroll Part 2 of the APEX trial which is expected to include approximately 65 AdvSM patients and is on-track to complete enrollment by the end of 2024.

Source: https://forextv.com/top-news/cogent-biosciences-announces-positive-initial-data-from-phase-2-summit-trial-evaluating-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm/

Cogent will host a webcast on Monday, December 11, 2023 at 8:00 a.m. ET (5:00 a.m. PT) to discuss the Part 1a data presented today at ASH and the APEX data being presented on Monday.

Source: https://forextv.com/top-news/cogent-biosciences-announces-positive-initial-data-from-phase-2-summit-trial-evaluating-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm/

Exchange Traded Concepts LLC grew its holdings in Cogent Communications by 71.2% in the fourth quarter.

Source: https://www.etfdailynews.com/2023/05/25/belpointe-asset-management-llc-acquires-new-holdings-in-cogent-communications-holdings-inc-nasdaqccoi/

Finally, KeyCorp raised shares of Cogent Communications from a “sector weight” rating to an “overweight” rating and set a $64.00 target price for the company in a research note on Tuesday, September 27th.

Source: https://www.etfdailynews.com/2023/01/15/assenagon-asset-management-s-a-has-1-16-million-holdings-in-cogent-communications-holdings-inc-nasdaqccoi/

Finally, TheStreet downgraded Cogent Communications from a “b-” rating to a “c+” rating in a report on Thursday, November 9th.

Source: https://www.dailypolitical.com/2023/12/02/great-west-life-assurance-co-can-has-2-72-million-position-in-cogent-communications-holdings-inc-nasdaqccoi.html

Needham & Company LLC began coverage on shares of Cogent Biosciences in a research report on Wednesday, December 14th.

Source: https://www.americanbankingnews.com/2023/03/04/boothbay-fund-management-llc-sells-13748-shares-of-cogent-biosciences-inc-nasdaqcogt.html

RA Capital Management L.P. bought a new stake in shares of Cogent Biosciences during the third quarter worth $59,881,000.

Source: https://www.americanbankingnews.com/2023/02/09/analysts-offer-predictions-for-cogent-biosciences-inc-s-q1-2023-earnings-nasdaqcogt.html

Royal Bank of Canada lifted their price target on Cogent Communications from $69.00 to $74.00 and gave the company an “outperform” rating in a research note on Tuesday, September 5th.

Source: https://www.dailypolitical.com/2023/11/11/cogent-communications-nasdaqccoi-shares-gap-down-to-65-71.html

Royal Bank of Canada lifted their price target on shares of Cogent Communications from $61.00 to $69.00 and gave the company an “outperform” rating in a research report on Tuesday, March 7th.

Source: https://www.etfdailynews.com/2023/05/23/citigroup-inc-acquires-11975-shares-of-cogent-communications-holdings-inc-nasdaqccoi/

Signaturefd LLC raised its holdings in Cogent Communications by 50.8% in the 3rd quarter.

Source: https://www.etfdailynews.com/2023/06/08/american-international-group-inc-trims-stake-in-cogent-communications-holdings-inc-nasdaqccoi/

The financial position of Cogent Biosciences, Inc. displays a for investors interested in a pioneering organization committed to creating transformative therapies.

Source: https://seekingalpha.com/article/4607816-cogent-biosciences-apex-part-2-launched-erbb2-fgfr2-on-track?source=feed_all_articles